EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review

Jin Li, Yu-Bo Liang, Qing-Bo Wang, Wan-Ling Luo, Xing-Ming Chen, Yawhan Lakang, Zi-Sheng Yang, Jin-Xiang Zuo, Yu-Kai Li, Zhiwei Li, Yong Peng, Yong-Bin Chen und 1 weitere

Liver Cancer · 31.10.2025 · 1-20

DOI: 10.1159/000549355 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver Cancer, online erschienen am 31.10.2025. Verfasst von Jin Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Rechallenge with immune checkpoint inhibitors (ICIs) has recently emerged as a potential therapeutic strategy for patients with hepatocellular carcinoma (HCC) who discontinue initial immunotherapy due to disease progression, immune-related adverse events (irAEs), or treatment completion. However, there are no standardized rechallenge regimen, patient indications, and few studies on its mechanism. Summary: This review provided a comprehensive, up-to-date summary on the clinical evidence, treatment regimens, patient characteristics, and biological rationale underlying ICI rechallenge for HCC patients. Current studies have identified four main rechallenge strategies according to the combinations of agents used in the initial and rechallenge treatments, most of which involve targeted therapy combined with anti-PD-L1 or dual ICIs. Across published studies, ICI rechallenge has shown variable but notable antitumor activity with an acceptable safety profile. Clinical benefits appear to be more frequently observed in HCC patients with preserved liver function, age

Schlagwörter

Stichwörter der Autor:innen

EfficacyHepatocellular carcinomaImmune checkpoint inhibitorImmune-related adverse eventsRechallenge

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Center for Molecular Oncology, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Genetic Evolution and Animal Models, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
  • Department of Surgical Education and Research, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
  • Yunnan Yunke Biotechnology Institution, Kunming, China.

Zitieren

APA

Li, J., Liang, Y. B., Wang, Q. B., Luo, W. L., Chen, X. M., Lakang, Y., Yang, Z. S., Zuo, J. X., Li, Y. K., Li, Z., Peng, Y., Chen, Y. B., & Ke, Y. (2025). Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review. Liver Cancer, 1-20. https://doi.org/10.1159/000549355

Vancouver

Li J, Liang YB, Wang QB, Luo WL, Chen XM, Lakang Y, et al. Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review. Liver Cancer. 2025:1-20. doi:10.1159/000549355

BibTeX
@article{Li2025,
  author = {Li, Jin and Liang, Yu-Bo and Wang, Qing-Bo and Luo, Wan-Ling and Chen, Xing-Ming and Lakang, Yawhan and Yang, Zi-Sheng and Zuo, Jin-Xiang and Li, Yu-Kai and Li, Zhiwei and Peng, Yong and Chen, Yong-Bin and Ke, Yang},
  title = {Rechallenge with Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Narrative Review},
  journal = {Liver Cancer},
  year = {2025},
  pages = {1--20},
  doi = {10.1159/000549355}
}
Kostenlos starten →